GlobeNewsWire
05 Aug 2026, 10:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An FDA advisory committee concluded in a 9-3 non-binding vote that evidence did not support the efficacy of Capricor's lead candidate, Deramiocel, for DMD-associated cardiomyopathy. — Negative feedback from an FDA advisory panel on a lead product candidate is a primary catalyst for severe valuation drops in biotech companies.
-0.90FDA briefing documents revealed concerns regarding post-hoc changes to Capricor's statistical analysis plan for the PUL 2.0 primary endpoint shortly before database unblinding. — Allegations of manipulating statistical plans to improve results severely undermine the credibility of clinical data and the likelihood of regulatory approval.
-0.70The FDA previously issued a Complete Response Letter stating the Deramiocel application failed to meet statutory requirements for substantial evidence of effectiveness. — A CRL indicates a fundamental failure to secure approval, necessitating more costly and time-consuming clinical trials.
-0.50Continue reading
6 related stories
Top 1 mover · tap to explore
A class action lawsuit has been filed against Capricor Therapeutics and its executives for securities fraud following a significant stock price decline. — While common after a crash, a securities fraud lawsuit creates additional legal liabilities and governance risks for the company.
-0.40Which stocks this story touches
Facing a class action lawsuit for securities fraud following a massive stock drop and FDA concerns over its lead product candidate.
Mentioned as being hit with a securities fraud investigation over alleged revenue misrepresentations.
Mentioned as being hit with a securities fraud class action over alleged misrepresentations about insulin pens.
Mentioned only in the context of a past legal recovery by the law firm.
Mentioned only in the context of a past legal recovery by the law firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
